First-in-Class Intranasal Epinephrine Spray for Anaphylaxis: Dose Finding Clinical Study

Lapidot, Tair et al. Journal of Allergy and Clinical Immunology: Global, Volume 0, Issue 0, 100487

Abstract

Background

Anaphylaxis is a life-threatening clinical presentation of acute systemic allergic reactions. Timely administration of epinephrine, usually by intramuscular autoinjector, is a robust life-saving treatment. Despite the critical necessity, there are multiple deterrants to patients’ proper use of epinephrine autoinjectors. FMXIN002 is a novel nasal dry powder formulation of epinephrine in a single-use device, offering first-in-class alternative treatment.

Objective

To measure epinephrine pharmacokinetics, pharmacodynamics and safety following a single administration of FMXIN002 at doses of 3.6 and 4.0 mg epinephrine versus IM autoinjector 0.3 mg, in healthy adults.

Methods

An open-label, single-dose, three-treatment, crossover, randomized, comparative bioavailability study with 12 healthy adults, female and male. FMXIN002 stability was also tested.

Results

FMXIN002 4.0 mg was absorbed faster and higher by most of the subjects, compared to IM autoinjector. 91% of subjects achieved the clinical threshold of 100 pg/mL plasma epinephrine at 6 minutes after administration of FMXIN002 4.0mg compared to 55% of subjects treated with IM autoinjector.

Association of ulcerative colitis with atopic dermatitis: identification of shared and unique mechanisms by construction and computational analysis of disease maps

Oxana Lopata, Marcio Luis Acencio, Xinhui Wang, Ahmed Abdelmonem Hemedan, Michael J. Chao, Scott A Jelinsky, Florian Tran, Philip Rosenstiel, Andrew Y.F. Li Yim, Reinhard Schneider, Venkata Satagopam, Marek Ostaszewski bioRxiv 2025.04.23.650149; doi: https://doi.org/10.1101/2025.04.23.650149

ABSTRACT

Background and Aims Ulcerative colitis (UC) and atopic dermatitis (AD) are immune-mediated inflammatory diseases with limited treatment options. They are known to be related which may explain higher risk of development of UC in patients with AD. The goal of this work is to review and analyse molecular mechanisms of UC in comparison to AD towards insights into UC complexity, potential comorbidities and novel therapies.

Methods We developed graphical computational models of UC and AD molecular mechanisms (disease maps) by integrating information from over 800 manually curated articles. The maps are available online at https://imi-immuniverse.elixir-luxembourg.org. Disease-specific risk variants and gene expression profiles are visualised to identify signatures specific to UC, and shared with AD.

National best practice guidelines for anaphylaxis prevention and management in Australian schools

Netting, Merryn J. et al. Journal of Allergy and Clinical Immunology: Global, Volume 4, Issue 2, 100413

Abstract

Background

Anaphylaxis prevention and management in the school setting is an important health and safety issue as the rates of food allergy in children continue to increase.

Objective

We describe the development and review of the Australian National Allergy Council best practice guidelines for anaphylaxis prevention and management in schools.

Methods

Developed in consultation with key stakeholders in health and education settings, the best practice guidelines incorporate 7 key recommendations for anaphylaxis prevention and management: an allergy aware approach; anaphylaxis management policy and plans; allergy documentation; emergency response; staff training; community and student education; and postincident management and incident reporting.

Reduction in Artemisia Pollen-Specific IgE Levels During House Dust Mite Allergen Immunotherapy in Polysensitized Allergic Rhinitis Patients: A Three-Year Retrospective Study in Northern, China

Sun X, Li X, Gao T, Liu P, Liu N, Jin P, Zhi L. J Asthma Allergy. 2025;18:665-673 https://doi.org/10.2147/JAA.S525620

Abstract

Background:  Allergen immunotherapy (AIT) is a well-established treatment for allergic diseases, particularly in patients with allergic rhinitis and asthma. In regions where patients are polysensitized, AIT can have broader immunomodulatory effects. This study investigates the impact of house dust mite AIT on IgE responses to both dust mites and non-target allergens, specifically Artemisia pollen, in polysensitized allergic rhinitis patients.

Methods:  This retrospective study included polysensitized patients aged 18 or older with a diagnosis of allergic rhinitis or rhinitis with asthma and positive IgE for both house dust mites and Artemisia pollen. Patients who completed at least three years of AIT for house dust mites were included. IgE levels for Dermatophagoides pteronyssinus (Der p), Dermatophagoides farinae (Der f), and Artemisia pollen were measured at baseline and after 1, 2, and 3 years of treatment.

Canadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical Therapies

Gooderham, M.J., Hong, H.Ch., Lynde, C. et al.  Dermatol Ther (Heidelb) (2025). https://doi.org/10.1007/s13555-025-01386-2

Abstract

Introduction

Atopic dermatitis (AD) is a highly prevalent disease in Canada with significant patient burden. Treatment guidance for topical therapy (the mainstay of AD management), with particular consideration of emerging treatments, may further improve patient care. Here, we aim to provide healthcare professionals with AD treatment recommendations from the perspective of 10 Canadian dermatologists with expertise in managing AD.

Methods

The panel of dermatologists conducted a systematic literature review and leveraged their clinical experience to develop generally accepted principles, consensus statements, and a treatment algorithm using an iterative consensus process.

Results

The panel collectively developed six generally accepted principles, 10 consensus statements, and a treatment algorithm. The guidance notes that assessment of disease severity should encompass both physician-rated measures and patient-reported outcomes. Disease education, lifestyle-based strategies (e.g., trigger avoidance), and supportive measures (e.g., moisturizers) can help reduce signs and symptoms of AD.

Oral Immunotherapy in Peanut-Allergic Adults Using Real-World Materials

Hunter H, Ue KL, Cornelius V, Yung CC, Thomas I, Tsilochristou O, Layhadi J, Siew LQC, Venter C, Shamji MH, Till SJ. Allergy. 2025 Apr 23. doi: 10.1111/all.16493. 

ABSTRACT

Background

Peanut oral immunotherapy (OIT) has shown effectiveness in achieving desensitization of children; however, evidence in adults is lacking.

Methods

Graphical Abstract

This phase II trial evaluated peanut OIT in peanut-allergic adults using real-world peanut products. A Simon's minimax two-stage design, incorporating a stop:go for futility, was employed.

Herpes Zoster Vaccination and Dementia Occurrence

Pomirchy M, Bommer C, Pradella F, Michalik F, Peters R, Geldsetzer P. JAMA. 2025 Apr 23:e255013. doi: 10.1001/jama.2025.5013.

Key Points

Question  What is the effect of herpes zoster vaccination on the probability of receiving a new diagnosis of dementia?

Findings  In this quasi-experimental study using electronic health record data from Australia, being eligible for herpes zoster vaccination based solely on date of birth significantly decreased the probability of receiving a new dementia diagnosis during 7.4 years by 1.8 percentage points.

Meaning  By taking advantage of a quasi-experiment, this study provides evidence for a beneficial effect of herpes zoster vaccination for preventing or delaying dementia that is more likely to be causal than the associations reported in the existing correlational evidence.

Abstract

Importance  Recent evidence from a quasi-experiment in Wales showed that herpes zoster (HZ) vaccination appears to prevent or delay dementia.

Urticaria and other mimickers of urticaria

Rojo-Gutierrez MI, Moncayo-Coello CV, Macias Weinmann A, Gomez RM, Ensina LF, Cherrez-Ojeda I, Piraino Sosa P, Latour Staffeid P, Valentin Rostan M.  Front Allergy. 2025 Feb 13;5:1522749. doi: 10.3389/falgy.2024.1522749. 

Abstract

Urticaria is a mast cell-dependent skin disease characterized by the presence of hives, angioedema, or both in the absence of systemic symptoms. It may be acute, or chronic. (1) Acute urticaria (AU) is common in children, affecting boys and girls equally. Chronic urticaria (CU) affects adult women more (3). AU affects more than 20% of the population and CU 0.1 and 1.5%. There are many pathologies that do not meet the clinical criteria for urticaria, despite being called urticarias, which leads to erroneous diagnoses and inconclusive epidemiology.